Risk factors
TScan Therapeutics (TCRX) risk factors
Item 1A of every TScan Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
119 risks, 5 new, 7 dropped, 16 reworded since the prior year. TScan announced a 30 percent workforce reduction cutting 66 roles to prioritize strategy. The company is advancing an early-stage in vivo engineering platform for solid tumors. New trade policies under the Trump administration and tax code updates like Section 174 were incorporated.
Filed Mar 04, 2026 - FY2024 10-K risk factors
121 risks. TScan faces heavy financial risks with sustained operating losses and reliance on external financing, including a $52.5 million loan facility with Silicon Valley Bank.
Filed Mar 05, 2025